Safety and Efficacy of Subcutaneous Daratumumab

POSB72 Subcutaneous Daratumumab in the Treatment of Multiple ...

A daratumumab formulation for subcutaneous administration (dara-SC) was developed with the goal of shortening treatment duration without compromising safety and ...

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide ...

Importance Recently, the benefit of adding daratumumab to the proteasome inhibitor–based, 3-drug combination of bortezomib, lenalidomide, and ...

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma

The subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone showed significant improvement in ...

Teclistamab in Combination with Subcutaneous Daratumumab and ...

The combination of daratumumab (dara) and lenalidomide (len) plus dexamethasone is approved for the treatment of MM.

results from the randomized, open-label, phase III LIGHTHOUSE study

The overall safety profile of melflufen in triplet combination with daratumumab and dexamethasone was consistent with the known safety profile ...

Efficacy and safety of intravenous daratumumab-based treatments ...

Intravenous daratumumab (DARA IV) has been increasingly used in the treatment of amyloid light-chain (AL) amyloidosis.

daratumumab (subcut) - Cancer Care Ontario

The safety and efficacy of daratumumab (subcut) have not been established in children < 18 years of age. back to top. F - Administration Guidelines. Daratumumab ...

Daratumumab (intravenous route) - Mayo Clinic

This medicine may cause an infusion reaction, including anaphylaxis, which can be life-threatening and requires immediate medical attention.

Subcutaneous Daratumumab in Patients with Relapsed ... - YouTube

... safety or efficacy of daratumumab, an open-label, multicenter, phase 1b clinical trial (PAVO; NCT02519452) was conducted to evaluate a ...

Subcutaneous Daratumumab Is Non-Inferior in Asian Patients ...

... subcutaneous daratumumab was non-inferior to intravenous daratumumab ... Subcutaneous Daratumumab Is ... efficacy and safety in relapsed or refractory MM.

a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Subcutaneous daratumumab was non-inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety ...

DARZALEX-pi.pdf - Janssen

of daratumumab and hyaluronidase for subcutaneous injection: ... Safety and effectiveness of DARZALEX in pediatric patients have not been established.

761145Orig1s000 - accessdata.fda.gov

In conclusion, the efficacy and safety of daratumumab SC monotherapy was comparable to daratumumab IV monotherapy. Daratumumab SC offers a.

Darzalex, INN-daratumumab

profile for DARZALEX subcutaneous formulation and intravenous daratumumab ... MMY2040 was an open-label trial evaluating the efficacy and safety of DARZALEX ...

Talquetamab/Daratumumab Shows Durable Responses in R/R ...

... subcutaneous daratumumab and ... Evaluation of efficacy and safety of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab ...

Adding daratumumab to VRd results in improved PFS in multiple ...

Given this potential, and based on the initial safety and efficacy results observed in the phase II study MMY2004, this phase III study was ...

Evaluation of administration-related reactions with subcutaneous ...

Dara-SQ was shown to be non-inferior to intravenous daratumumab (Dara-IV) in efficacy, safety, and associated with fewer administration ...

Efficacy and Safety of Durvalumab Combined with Daratumumab in ...

Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will ...

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous ...

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) · Timeline · Sponsor of this trial · Details and patient ...

Technology name [formulation]* for indication [– first/second/third line]*

intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered ... years; daratumumab subcutaneous vs daratumumab ...